The trial, which is still in progress, is the result of a collaboration between GSK,
the PATH Malaria Vaccine Initiative and a number of research institutes around the world.
Standing at the intersection of
malaria and immunization, MVI is part of PATH's Center for Malaria Control and Elimination and PATH's Center for Vaccine Innovation and
malaria and immunization, MVI is part of
PATH's Center for
Malaria Control and Elimination and PATH's Center for Vaccine Innovation and
Malaria Control and Elimination and
PATH's Center for
Vaccine Innovation and Access.